Patienterne randomiseredes (2: 1) til enten dasatinib (70 mg 2 gange daglig) eller imatinib (400 mg 2 gange daglig).
They were randomised (2:1) to either dasatinib (70 mg twice daily) or imatinib (400 mg twice daily).